The DTD1 Knockout HEK293T Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the human DTD1 gene in HEK293T cells. This product provides a mixed population of cells with heterogeneous target-gene disruptions, enabling loss-of-function studies of D-tyrosyl-tRNA deacylase in a readily transfectable human embryonic kidney epithelial model. The polyclonal format retains the genetic variability of the edited pool, making it suitable for pooled screening approaches and functional assays that do not require clonal homogeneity. As a CRISPR/Cas9-mediated gene disruption model, these cells facilitate investigation of translational quality control without the need for single-cell cloning or biallelic knockout validation.
The HEK293T host cell line is derived from human embryonic kidney cells transformed with sheared adenovirus type 5 DNA and further modified to stably express the SV40 large T antigen. This genetic background confers high transfection efficiency and robust protein expression, making HEK293T a workhorse for viral production, transient gene expression, and biochemical studies. As an epithelial cell line, HEK293T retains features relevant to kidney cell biology while offering experimental tractability for interrogating fundamental cellular processes, including translation, protein homeostasis, and metabolic regulation.
DTD1 encodes a D-tyrosyl-tRNA deacylase that hydrolyzes D-aminoacyl-tRNAs, specifically D-tyrosyl-tRNA, to prevent the misincorporation of D-amino acids into elongating polypeptide chains. This activity is critical for maintaining translational fidelity and proteostasis. DTD1 function is integrated into a network involving amino acid availability, mTORC1 signaling, and cellular stress responses; upstream regulators such as nutrient sensing pathways modulate its expression, while downstream targets include translational accuracy and proteostasis network components. The enzyme interacts directly with tRNA substrates and ribosomal machinery, and acts in concert with tyrosyl-tRNA synthetase and ribosomal subunits to ensure that only L-amino acids are utilized during protein synthesis.
In HEK293T cells, disruption of DTD1 creates a model to study how loss of D-aminoacyl-tRNA editing impacts translational quality control within a kidney-derived, highly proliferative cellular context. Given that HEK293T cells are extensively employed for recombinant protein production and functional assays, DTD1 knockout in this background may reveal consequences of impaired editing on protein synthesis fidelity, cellular responses to amino acid imbalance, and stress-associated pathways. This system is particularly relevant for exploring links between translational errors, cancer cell metabolism, and neurodegeneration, where disturbances in proteostasis are implicated.
Researchers can employ the DTD1 Knockout HEK293T Polyclonal Cells in a variety of experimental approaches, including western blotting to confirm DTD1 loss, D-amino acid toxicity assays, translational fidelity reporters, and mass spectrometry-based detection of D-amino acid incorporation. Additional applications encompass cell viability and proliferation assays under amino acid starvation, tRNA charging analyses, and ribosome profiling to assess genome-wide translation dynamics. These tools enable dissection of amino acid homeostasis, protein quality control, and stress adaptation pathways. For further information and technical assistance, please contact Ascent Research.
